Branford biotech Azitra has doubled its lifetime venture capital fundraising with a $17 million round led by the investment arm of pharma giant Bayer.
Azitra said it would use the Series B funding to advance its development of dermatological medicines and natural skin-care products that leverage the good bacteria that live on the skin, known as the skin microbiome.